-

10:59:58 PM

LIVE Real Time EXEL Stock Market News

EXEL - Exelixis Inc

05/06/21 4:05 PM

Nasdaq : EXEL

Exelixis Announces First Quarter 2021 Financial Results and Provides Corporate Update

Exelixis, Inc. (Nasdaq: EXEL) today reported financial results for the first quarter of 2021 and provided an update on progress toward achieving key corporate objectives, as well as commercial, clinical and pipeline development milestones."The Exelixis team made significant progress across all

RHEA-AI

very positive

05/04/21 8:00 AM

Nasdaq : EXEL

Exelixis Expands its Biotherapeutics Portfolio with Acquisition of GamaMabs Pharma's First-in-Class Humanized Antibody Program Against a Novel Oncology Target

Exelixis, Inc. (Nasdaq: EXEL) and GamaMabs Pharma SA today announced that they have entered into an agreement under which Exelixis will, upon the future closing of the asset purchase and subject to certain conditions to closing, acquire all rights, title and interest in GamaMabs' AMHR2 antibody

RHEA-AI

neutral

04/27/21 4:05 PM

Nasdaq : EXEL

Exelixis to Webcast Fireside Chats as Part of Virtual Investor Conferences in May

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will participate in fireside chats at the following virtual investor conferences in May:7 th Annual Truist Securities Life Sciences Summit: Exelixis is scheduled to

RHEA-AI

neutral

04/22/21 4:05 PM

Nasdaq : EXEL

Exelixis to Release First Quarter 2021 Financial Results on Thursday, May 6, 2021

Exelixis, Inc. (Nasdaq: EXEL) announced today that its first quarter 2021 financial results will be released on Thursday, May 6, 2021 after the markets close. At 5:00 p.m. EDT / 2:00 p.m. PDT, Exelixis management will host a conference call and webcast to discuss the results and provide a general

RHEA-AI

neutral

04/05/21 8:00 AM

Nasdaq : EXEL

Exelixis Announces U.S. FDA Accepts Investigational New Drug Application for XB002 in Patients with Advanced Solid Tumors

Exelixis, Inc. (Nasdaq: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug Application (IND) to evaluate the safety, tolerability, pharmacokinetics and preliminary antitumor activity of XB002 in patients with advanced solid tumors. As a

RHEA-AI

neutral

03/31/21 1:01 AM

Nasdaq : EXEL

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX(R) (cabozantinib) in Combination with OPDIVO(R) (nivolumab) as First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

Exelixis, Inc. (Nasdaq: EXEL) today announced its partner Ipsen received approval from the European Commission (EC) for CABOMETYX (R) (cabozantinib) in combination with OPDIVO (R) (nivolumab) as a first-line treatment for advanced renal cell carcinoma (RCC). This approval allows for the marketing of

RHEA-AI

very positive

03/30/21 8:00 AM

Nasdaq : EXEL

Exelixis Announces Enrollment Completion in Phase 3 COSMIC-313 Pivotal Trial of Cabozantinib in Combination with Nivolumab and Ipilimumab Versus Nivolumab and Ipilimumab in Previously Untreated Advanced Renal Cell Carcinoma

Exelixis, Inc. (Nasdaq: EXEL) today announced that COSMIC-313, the phase 3 pivotal trial evaluating the combination of cabozantinib (CABOMETYX (R)), nivolumab (OPDIVO (R)) and ipilimumab (YERVOY (R)) versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced

RHEA-AI

neutral

03/18/21 8:00 AM

Nasdaq : EXEL

Exelixis Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany and Pfizer to Evaluate XL092 and Avelumab in Various Forms of Locally Advanced or Metastatic Urothelial Carcinoma

Exelixis, Inc. (Nasdaq:EXEL) today announced a clinical trial collaboration and supply agreement with Merck KGaA, Darmstadt, Germany and Pfizer for the ongoing phase 1b dose escalation study STELLAR-001 (previously called "XL092-001"), adding three new cohorts that will evaluate the safety and

RHEA-AI

neutral

03/08/21 8:00 AM

Nasdaq : EXEL

Exelixis Enters into Exclusive License Agreement with WuXi Biologics to Support Further Expansion of its Growing Oncology Biologics Pipeline

Exelixis, Inc. (Nasdaq: EXEL) and WuXi Biologics ("WuXi Bio") (2269.HK) today announced the companies have entered into an exclusive license agreement to support the continued expansion of Exelixis' oncology biologics pipeline. The agreement is the latest in a series of biologics-focused

RHEA-AI

very positive

02/26/21 6:30 AM

Nasdaq : EXEL

Exelixis' Partner Ipsen Receives Positive CHMP Opinion for CABOMETYX(R) (cabozantinib) in Combination with OPDIVO(R) (nivolumab) as a First-Line Treatment for Patients with Advanced Renal Cell Carcinoma

Exelixis, Inc. (NASDAQ: EXEL) today announced that its partner Ipsen received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), for CABOMETYX(R) (cabozantinib) in combination with OPDIVO(R) (nivolumab) for

RHEA-AI

very positive